Composition of the preparation per 1 ml:
bioactive concentrate of small marine fish 0.1 ml;
phenol not more than 0.005 g,
water for injection up to 1 ml.
Pharmacotherapeutic group: tissue repair stimulant of natural origin
ATX code: М09АХ
Alflutop is a chondroprotector, the active component of which is a bioactive concentrate from small sea fish. The concentrate contains mucopolysaccharides (chondroitin sulfate), amino acids, peptides, sodium, potassium, calcium, magnesium, iron, copper and zinc ions.
Alflutop prevents the destruction of macromolecular structures of normal tissues, stimulates recovery processes in interstitial tissue and articular cartilage tissue, which explains its analgesic effect.
The anti-inflammatory effect and tissue regeneration are based on the inhibition of the activity of hyaluronidase and the normalization of the biosynthesis of hyaluronic acid.
Both of these effects are synergistic and cause the activation of regenerative processes in tissues (in particular, restoration of the cartilage structure).
The active component of the preparation is a bioactive concentrate from small sea fish (Sprat North Sea (Sprattus sprattus sprattus), herring family (Clupeidae);
Black Sea Merlang (Odontogadus merlangus euxinus), cod family (Gadidae);
Black Sea Puzzler (Alosa tanaica nordmanni), herring family (Clupeidae);
Black Sea anchovy (Engraulis encrasicholus ponticus), anchovy family (Engraulidae) obtained by extraction followed by deproteinization and delipidization.
Application during pregnancy and lactation
Hypersensitivity to the components of the drug.
Pregnancy and the period of breastfeeding.
Children under 18 years of age (due to the lack of clinical data in this category of patients).
Side effects are grouped according to the WHO classification of the incidence of adverse reactions: very often (? 1/10), often (? 1/100 to <1/10), infrequently (? 1/1000 to <1/100), rarely ( ≥1 / 10000 to <1/1000), very rare (<1/10000), the frequency is unknown (the frequency cannot be determined from the available data).
Rarely: itchy dermatitis, skin redness and burning sensation at the injection site, short-term myalgias. Very rare: development of anaphylactic reactions. The frequency is unknown: with intra-articular injections, a transient increase in pain is possible.
How to take, course and dosage
For polyosteoarthritis and osteochondrosis, the drug is administered deeply intramuscularly:
- 1 ml per day, the course of treatment is 20 injections (1 injection per day for 20 days)
- 2 ml every other day, the course of treatment is 10 injections (1 injection every other day for 20 days).
With a predominant lesion of large joints, the drug is injected intra-articularly in 1 - 2 ml into each joint with an interval of 3 - 4 days. A total of 5 - 6 injections in each joint for a course.
A combination of intra-articular and intramuscular methods of administration is possible.
It is advisable to repeat the course of treatment 6 months after consulting a doctor.
Influence on the ability to drive vehicles and mechanisms
The use of the drug does not affect the ability to perform potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions (driving, working with moving mechanisms, the work of a dispatcher and an operator).
In a dark place at a temperature of 15 ° C to 25 ° C.
Keep out of the reach of children.